This is a working overview of incretin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-14. Anything still debated is marked as such rather than presented as settled.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
14 October – NASA launches the Europa Clipper from Kennedy Space Center, which will study the Jovian moon Europa while orbiting Jupiter. 15 October – Physicists and Researchers from the Institute of Nuclear Physics of the Polish Academy of Sciences achieve the first coherent picture of atomic nuclei made from only quarks and gluons, fusing this picture with the model of nuclei made from protons and neutrons. 16 October – Researchers at the University of Birmingham Medical School encounter a human cadaver with three penises. 17 October Scientists observe a black hole corona using NASA's Imaging X-ray Polarimetry Explorer, and determine its shape for the first time. A study of 25 crowdsourced ideas aimed at reducing political polarisation in the United States is published in the journal Science. Scientists build the world's smallest quantum computer using a single photon. 19 October – Researchers develop a plant-based food supplement to protect bees' brains from neurotoxins. 23 October Physicists observe a "black hole triple" for the first time. Astronomers using NASA/ESA's James Webb Space Telescope detect the first brown dwarf candidates outside the Milky Way in NGC 602. Scientists works on ways to remove CO2 from the air as levels rise. One method, called direct air capture, uses a strong material (COF with amines) that can absorb and release CO2 at low temperatures. It fits into machines that already capture CO2 from factories. 28 October – A study of the Uranian moon Miranda finds that it may contain a deep ocean of water below its surface.
== Controversial terminology == A toxic heavy metal is a common but misleading term for a metal-like element noted for its potential toxicity. Not all heavy metals are toxic and some toxic metals are not heavy. The International Union of Pure and Applied Chemistry (IUPAC), which standardizes nomenclature, says the term "'heavy metals' is both meaningless and misleading". The IUPAC report focuses on the legal and toxicological implications of describing "heavy metals" as toxins when there is no scientific evidence to support a connection. The density implied by the adjective "heavy" has almost no biological consequences, and pure metals are rarely the biologically active substance. This characterization has been echoed by numerous reviews. The most widely used toxicology textbook, Casarett and Doull's Toxicology, uses "toxic metal", not "heavy metals". Nevertheless many scientific and science-related articles, including medical texts, continue to use "heavy metal" as a term for toxic substances.
== Medical use == Polymyxin antibiotics are relatively neurotoxic and nephrotoxic, so are usually used only as a last resort if modern antibiotics are ineffective or are contraindicated. Typical uses are for infections caused by strains of multiple drug-resistant Pseudomonas aeruginosa or carbapenemase-producing Enterobacteriaceae. Polymyxins have less effect on Gram-positive organisms, and are sometimes combined with other agents (as with trimethoprim/polymyxin) to broaden the effective spectrum. Polymyxins B are not absorbed from the gastrointestinal tract, so they are only administered orally if the goal is to disinfect the GI tract. Another route of administration is chosen for systemic treatment, e.g., parenteral (often intravenously) or by inhalation. They are also used externally as a cream or drops to treat otitis externa (swimmers ear), and as a component of triple antibiotic ointment to treat and prevent skin infections.
Sources: en.wikipedia.org
A topogenic sequence is a collective term used for a peptide sequence present at nascent proteins essential for their insertion and orienting in cellular membranes. The sequences are also used to translocate proteins across various intracellular membranes, and ensure they are transported to the correct organelle after synthesis. The position of the sequence may be at the end, e.g. N-terminal signal sequence, or in mid parts of the nascent protein, e.g. stop-transfer anchor sequences and signal-anchor sequences. If the sequence is at the end of the polypeptide, it is cleaved off after entering the ER-lumen (via a translocon) by a signal peptidase, and subsequently degraded. As an example, the vast majority of all known complex plastid preproteins (an 'unactivated' protein) encoded in the nucleus possess a topogenic sequence.
In Hungary, a government advisory body recommended mephedrone should be made illegal in August 2010, which was followed, making it illegal in January 2011; Spain followed in February 2011. Mexico, by decree, outlawed mephedrone as a substance "with low or no therapeutical use which pose[s] a serious threat to public health" in 2014. In some countries, mephedrone is not specifically listed as illegal, but is controlled under legislation that makes compounds illegal if they are analogs of drugs already listed. In Australia during 2010, it was not specifically listed as prohibited, but the Australian Federal Police stated it is an analogue to methcathinone and therefore illegal. It is now listed as a Schedule 9 prohibited substance in Australia under the Poisons Standard (October 2015). A Schedule 9 substance is a substance which may be abused or misused, the manufacture, possession, sale or use of which should be prohibited by law except when required for medical or scientific research, or for analytical, teaching or training purposes with approval of Commonwealth and/or State or Territory Health Authorities. In February 2010, 22 men were arrested in connection with importing mephedrone. By January 2011, every state in Australia, other than Victoria, had listed it as a controlled drug.
The vaginal environment is slightly acidic, with pH ranging from 3.8 - 4.5 based on multiple factors such as age, natural bacteria, and stage of menstrual cycle. Due to the variety in possible pH values, this poses an interesting consideration for drug delivery. Absorption and release of drugs is often influenced by pH, so if the pH is changing through the menstrual cycle, different combinations could be needed at different times to achieve the most effective drug delivery system.
Sources: en.wikipedia.org
There are many diverse ways of monitoring enzyme levels through the use of enzyme inhibition. The general principle in many of these is the use the knowledge that many enzymes are driven by phosphate-releasing compounds such as adenosine triphosphate. Using radiolabelled 32P phosphate a fluorometric analysis can be used. Or unique polymers can be used to immobilize enzymes and act in an electrochemical biosensor. Overall, the benefits include a fast response time and little sample preparation. Some of the downsides include a lack of specificity in terms of being able to get readings of very small amounts of toxin and the rigidity of the assays in apply certain procedures to different toxins.
89. Mymensingh Med J. 2026 Oct;35(4):1312-1316. Diagnosis of Rhinoentomophthoromycosis in a 55 Years Old Male: A Case Report. Shawrave SA(1), Zoheb SJM, Galib GI, Tanni RZ, Shawon MMR, Bhuiyan MJT. Author information: (1)Dr Shaharior Arafat Shawrave, Associate Professor, Department of ENT and Head Neck Surgery, Dhaka Medical College (DMC), Dhaka, Bangladesh; E-mail: shawrave77@gmail.com. Entomophthoromycosis is a chronic fungal infection characterized by a diverse range of manifestations, including subcutaneous, mucocutaneous and visceral infections. The majority of subcutaneous infections caused by entomophthoralean fungi are attributed to Basidiobolus spp, C. coronatus or C. incongruous. In this report, we present a case of rhinoentomophthoromycosis in a middle-aged, immunocompetent male, primarily affecting the nasopharynx. Initially, the diagnosis posed a dilemma, but it was ultimately confirmed through meticulous examination of microscopy and histopathology of the aspirate. The patient's response to antifungal therapy was favorable. We hereby provide a comprehensive account of this case and discuss the efficacy of Posaconazole in the treatment of rhinoentomophthoromycosis in a 55-year-old male patient with diabetes.
=== Binder, emulsifier, and stabilizer === Gelatin is used as a carrier or separating agent for other substances. It makes β-carotene water-soluble, thus allowing it to be used as a coloring agent in soft drinks, imparting a yellow color. Certain professional and theatrical lighting equipment use color gels to change the beam color. Historically, these were made with gelatin, hence the term color gel. It is used to hold silver halide crystals in an emulsion in virtually all photographic films and photographic papers. Despite significant effort, no suitable substitutes with the stability and low cost of gelatin have been found. Gelatin is used as a binder in match heads and sandpaper. The culinary uses in clarification and fining as well as the medical use in drug stabilization are also examples of using gelatin as a emulsifier or a binder.
== Spatial xenon oscillations == Large thermal reactors with low flux coupling between regions may experience spatial power oscillations because of the non-uniform presence of xenon-135. Xenon-induced spatial power oscillations occur as a result of rapid perturbations to power distribution that cause the xenon and iodine distribution to be out of phase with the perturbed power distribution. This results in a shift in xenon and iodine distributions that causes the power distribution to change in an opposite direction from the initial perturbation. The instantaneous production rate of xenon-135 is dependent on the iodine-135 concentration and therefore on the local neutron flux history. On the other hand, the destruction rate of xenon-135 is dependent on the instantaneous local neutron flux. The combination of delayed generation and high neutron-capture cross section produces a diversity of impacts on nuclear reactor operation. The mechanism is described in the following four steps.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.